+ 0.60
+ 0.4%

GW Pharma Details Positive Results Of Epidiolex Study In Patients With TSC-Related Seizures

December 22, 2020 11:52 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
GW Pharma Details Positive Results Of Epidiolex Study In Patients With TSC-Related Seizures

GW Pharmaceuticals plc (NASDAQ:GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology.  

Epidiolex is the first FDA-authorized CBD medicine for treating children with severe forms of epilepsy. The medicine was first approved for treatments of seizures connected to Lennox-Gastaut syndrome and Dravet syndrome.

In July, the FDA also approved Epidiolex for managing seizures related to tuberous sclerosis complex.

Tuberous sclerosis complex is a genetic condition that causes the growth of tumors, usually benign ones, in vital organs, further causing genetic epilepsy.

Around 1 million people in the world suffer from the condition, which causes various types of seizures.

The results of the study JAMA Neurology published show that patients receiving Epidiolex as a treatment had considerably less TCS-associated seizures (48.6%) versus placebo (26.5%). This trial was the basis for the July 2020 FDA approval of Epidiolex for TSC-related seizures.

People living with TSC may experience focal seizures and spasms as infants and continue to suffer from seizures throughout their lifetime,” Elizabeth Thiele, M.D., Ph.D. said in a statement. 

Thiele is the director of pediatric epilepsy and director of The Carol and James Herscot Center for Tuberous Sclerosis Complex at Massachusetts General Hospital, a professor of neurology at Harvard Medical School, Boston and lead investigator of the trial . “This study demonstrated that for patients with TSC and a high baseline burden of treatment-resistant, primarily focal, seizures, Epidiolex significantly reduced the frequency of seizures compared with placebo.”

The safety profile in this study was aligned with observations from earlier studies of Epidiolex, GW Pharma said. 

 “The publication of these results in JAMA Neurology reinforces the importance of Epidiolex as a new treatment option for people experiencing treatment-resistant seizures associated with TSC,” CEO Justin Gover said in a statement.

“We hope that the data will help clinicians to better understand the potential of Epidiolex to reduce focal and generalized seizure frequency in their patients with this condition.”

Courtesy photo. 

Related Articles

The Week In Cannabis: Stocks Spike By Double Digits On Earnings, Strong Sales, Financings

Cannabis stocks widely outperformed the markets after a slew of financing deals and strong earnings reports. read more

HempFusion Wellness Debuts In Europe Via Deal With Ireland CPG Distributor

Health and wellness CBD company HempFusion Wellness Inc. (TSX: CBD.U) is expanding to Europe through a deal with an undisclosed consumer goods distributor in Ireland. read more

Vext Science Upsizes Bought Deal Public Offering To Raise $18M

Vertically integrated CBD company Vext Science Inc. (CSE: VEXT) (OTCQX: VEXTF) is poised to raise $18 million through a bought deal offering of its units. read more

From Peace Corps To Peace Pipes: Steve Sakala Shows CBD Companies How To Be Eco-Friendly

There's zero excuse for consumer packaged goods companies to not be plastic negative, says Steve Sakala. Take his work in the cannabis industry. Like most industries, the world of weed has a major sustainability problem. It creates at least 150 million tons of waste annually, mainly due to single-use plastic packaging. read more

New Cannabis Products: Canned Cocktails, Post-Workout CBD Seltzers, Flower Products, And Oral Strips

As the cannabis market expands, it's hard to keep track of the many products that launch every week. Benzinga put together a short list of some of the most interesting new cannabis products. read more